GlassScriptPhysician profile
Mandie Lin Shaw
NPI 1114475332
$4,440.20
in general payments reported to CMS, 2019-2025
22 companies · $1,026 in 2025
The $1,026 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $500 · 2022: $875 · 2023: $937 · 2024: $1,103 · 2025: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,065.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,100.48 | 2021-2025 | |
| Lundbeck LLC | $638.01 | 2021-2025 | Rexulti |
| Novo Nordisk INC | $337.29 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $199.48 | 2021-2025 | Caplyta |
| Astellas Pharma US INC | $178.42 | 2024-2025 | Veozah |
| Corium, LLC | $165.22 | 2022-2024 | Azstarys |
| Collegium Pharmaceutical, INC. | $122.71 | 2025 | Jornay Pm |
| Pfizer INC. | $114.15 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $95.88 | 2023-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $93.81 | 2021-2022 | |
| Axsome Therapeutics, INC. | $87.60 | 2023-2024 | Auvelity |
| Lilly USA, LLC | $63.64 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Supernus Pharmaceuticals, INC. | $60.30 | 2024 | Qelbree |
| Dexcom, INC. | $34.31 | 2023 | Dexcom G6 Transmitter |
| Alkermes, INC. | $32.50 | 2021-2025 | Lybalvi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $27.40 | 2024-2025 | Nuzyra |
| Idorsia Pharmaceuticals US INC | $18.89 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $16.61 | 2025 | Fanapt |
| Neurocrine Biosciences, INC. | $16.53 | 2024 | Ingrezza |
| Currax Pharmaceuticals LLC | $14.54 | 2024 | Contrave, Onzetra Xsail |
| Owp Pharmaceuticals, INC. | $11.93 | 2022 | |
| Genentech USA, INC. | $10.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandie Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.